Discounted Cash Flow
Addex Therapeutics Ltd. ADR
—
—
Average annual growth rates
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Endpoint CAGR (better for long term trend)
| Metric | 10-Year | 5-Year | 3-Year |
|---|---|---|---|
| Sales | — | — | — |
| Free Cash Flow | — | — | — |
| Average (FCF & NI) | — | — | — |
| Net Income | — | — | — |
Projected growth rate
—
—
%
%
Historical inputs (10 fiscal years)
| YEAR | Sales | Net Income | Free Cash Flow | Net Margin | EPS (diluted) |
|---|---|---|---|---|---|
| 2017 | — | $-3.3m | $-2.1m | — | $-0.25 |
| 2018 | $6.0m | $-1.6m (49.9%) | $1.7m (181.4%) | -27.2% | $-0.07 (72.0%) |
| 2019 | $2.8m (-54.3%) | $-14.8m (-798.6%) | $-9.5m (-645.7%) | -535.0% (-1865.8%) | $-0.56 (-700.0%) |
| 2020 | $3.6m (30.8%) | $-12.9m (13.0%) | $-12.2m (-28.7%) | -355.9% (33.5%) | $-0.48 (14.3%) |
| 2021 | $2.9m (-19.3%) | $-15.4m (-19.4%) | $-14.7m (-20.4%) | -526.4% (-47.9%) | $-0.45 (6.2%) |
| 2022 | $1.4m (-51.2%) | $-10.0m (34.9%) | $-16.4m (-11.5%) | -703.0% (-33.6%) | $-0.46 (-2.2%) |
| 2023 | $1.6m (13.4%) | $-8.1m (19.4%) | $-8.0m (51.3%) | -499.5% (29.0%) | $-0.14 (69.6%) |
| 2024 | $404.1k (-74.9%) | $12.0m (248.5%) | $-5.4m (32.8%) | 2960.9% (692.8%) | $0.07 (150.0%) |
| 2025 | $30.0k (-92.6%) | $114.3k (-99.0%) | $114.3k (102.1%) | 381.5% (-87.1%) | $-0.06 (-185.7%) |
Base FCF: — (latest fiscal year)
Discount rate: % —
Terminal growth: —
Projection period: — years
Alt A decline yrs:
Alt B total yrs:
Projected cash flows
| Year | Projected cash flow | Discount Factor | Present Value |
|---|
PV of projected FCF: —
Terminal FCF: —
Terminal value: —
PV of terminal value: —
Enterprise value (DCF): —
Current price: —
—Alternative DCF Models
| Model | Fair Value | Upside | PV(FCFs) | PV(Terminal) | Total Years |
|---|---|---|---|---|---|
| Standard (10yr→TV) | — | — | — | — | 10 + TV |
| Alt A (Gradual Decline) | — | — | — | — | — |
| Alt B (30yr Hard Stop) | — | — | — | N/A | — |
This is a simplified DCF model for illustration. It uses reported free cash flow, a single growth assumption, fixed WACC, and a Gordon Growth terminal value. It is not investment advice.